nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftaroline fosamil—Hepatitis—Ifosfamide—testicular cancer	0.00574	0.00574	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Ifosfamide—testicular cancer	0.00567	0.00567	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Ifosfamide—testicular cancer	0.00563	0.00563	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Vinblastine—testicular cancer	0.00553	0.00553	CcSEcCtD
Ceftaroline fosamil—Erythema—Dactinomycin—testicular cancer	0.00545	0.00545	CcSEcCtD
Ceftaroline fosamil—Renal failure—Cisplatin—testicular cancer	0.00542	0.00542	CcSEcCtD
Ceftaroline fosamil—Anaemia—Bleomycin—testicular cancer	0.0054	0.0054	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00532	0.00532	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Etoposide—testicular cancer	0.0053	0.0053	CcSEcCtD
Ceftaroline fosamil—Pain—Chlorambucil—testicular cancer	0.00527	0.00527	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Cisplatin—testicular cancer	0.00521	0.00521	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Ifosfamide—testicular cancer	0.00521	0.00521	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Ifosfamide—testicular cancer	0.00518	0.00518	CcSEcCtD
Ceftaroline fosamil—Infestation—Etoposide—testicular cancer	0.00505	0.00505	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Etoposide—testicular cancer	0.00505	0.00505	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00504	0.00504	CcSEcCtD
Ceftaroline fosamil—Anaemia—Dactinomycin—testicular cancer	0.00504	0.00504	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Cisplatin—testicular cancer	0.00504	0.00504	CcSEcCtD
Ceftaroline fosamil—Erythema—Ifosfamide—testicular cancer	0.005	0.005	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Ifosfamide—testicular cancer	0.005	0.005	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Epirubicin—testicular cancer	0.00497	0.00497	CcSEcCtD
Ceftaroline fosamil—Renal failure—Etoposide—testicular cancer	0.00496	0.00496	CcSEcCtD
Ceftaroline fosamil—Urticaria—Chlorambucil—testicular cancer	0.0049	0.0049	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Cisplatin—testicular cancer	0.00489	0.00489	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Chlorambucil—testicular cancer	0.00487	0.00487	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Chlorambucil—testicular cancer	0.00487	0.00487	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Cisplatin—testicular cancer	0.00485	0.00485	CcSEcCtD
Ceftaroline fosamil—Constipation—Vinblastine—testicular cancer	0.00483	0.00483	CcSEcCtD
Ceftaroline fosamil—Pain—Vinblastine—testicular cancer	0.00483	0.00483	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Etoposide—testicular cancer	0.00478	0.00478	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Bleomycin—testicular cancer	0.00477	0.00477	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Bleomycin—testicular cancer	0.00467	0.00467	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Vinblastine—testicular cancer	0.00462	0.00462	CcSEcCtD
Ceftaroline fosamil—Anaemia—Ifosfamide—testicular cancer	0.00462	0.00462	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Doxorubicin—testicular cancer	0.0046	0.0046	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Chlorambucil—testicular cancer	0.00454	0.00454	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Etoposide—testicular cancer	0.00448	0.00448	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Cisplatin—testicular cancer	0.00447	0.00447	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Vinblastine—testicular cancer	0.00447	0.00447	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Etoposide—testicular cancer	0.00444	0.00444	CcSEcCtD
Ceftaroline fosamil—Palpitations—Ifosfamide—testicular cancer	0.00442	0.00442	CcSEcCtD
Ceftaroline fosamil—Pruritus—Chlorambucil—testicular cancer	0.00436	0.00436	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Dactinomycin—testicular cancer	0.00436	0.00436	CcSEcCtD
Ceftaroline fosamil—Convulsion—Ifosfamide—testicular cancer	0.00433	0.00433	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Cisplatin—testicular cancer	0.00431	0.00431	CcSEcCtD
Ceftaroline fosamil—Erythema—Cisplatin—testicular cancer	0.00431	0.00431	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Epirubicin—testicular cancer	0.00426	0.00426	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00422	0.00422	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Chlorambucil—testicular cancer	0.00422	0.00422	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Vinblastine—testicular cancer	0.00416	0.00416	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Etoposide—testicular cancer	0.00411	0.00411	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Etoposide—testicular cancer	0.00409	0.00409	CcSEcCtD
Ceftaroline fosamil—Pain—Bleomycin—testicular cancer	0.00408	0.00408	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Ifosfamide—testicular cancer	0.00408	0.00408	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Ifosfamide—testicular cancer	0.004	0.004	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Ifosfamide—testicular cancer	0.00399	0.00399	CcSEcCtD
Ceftaroline fosamil—Anaemia—Cisplatin—testicular cancer	0.00398	0.00398	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Ifosfamide—testicular cancer	0.00396	0.00396	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Doxorubicin—testicular cancer	0.00394	0.00394	CcSEcCtD
Ceftaroline fosamil—Vomiting—Chlorambucil—testicular cancer	0.00392	0.00392	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Vinblastine—testicular cancer	0.00387	0.00387	CcSEcCtD
Ceftaroline fosamil—Pain—Dactinomycin—testicular cancer	0.00381	0.00381	CcSEcCtD
Ceftaroline fosamil—Urticaria—Bleomycin—testicular cancer	0.00379	0.00379	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Bleomycin—testicular cancer	0.00377	0.00377	CcSEcCtD
Ceftaroline fosamil—Dizziness—Vinblastine—testicular cancer	0.00374	0.00374	CcSEcCtD
Ceftaroline fosamil—Convulsion—Cisplatin—testicular cancer	0.00373	0.00373	CcSEcCtD
Ceftaroline fosamil—Nausea—Chlorambucil—testicular cancer	0.00366	0.00366	CcSEcCtD
Ceftaroline fosamil—Anaemia—Etoposide—testicular cancer	0.00365	0.00365	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00364	0.00364	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00364	0.00364	CcSEcCtD
Ceftaroline fosamil—Vomiting—Vinblastine—testicular cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Headache—Vinblastine—testicular cancer	0.00354	0.00354	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Dactinomycin—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Dactinomycin—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Cisplatin—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Bleomycin—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Constipation—Ifosfamide—testicular cancer	0.00349	0.00349	CcSEcCtD
Ceftaroline fosamil—Pain—Ifosfamide—testicular cancer	0.00349	0.00349	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Cisplatin—testicular cancer	0.00345	0.00345	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Cisplatin—testicular cancer	0.00344	0.00344	CcSEcCtD
Ceftaroline fosamil—Convulsion—Etoposide—testicular cancer	0.00342	0.00342	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Cisplatin—testicular cancer	0.00341	0.00341	CcSEcCtD
Ceftaroline fosamil—Pruritus—Bleomycin—testicular cancer	0.00338	0.00338	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Methotrexate—testicular cancer	0.00336	0.00336	CcSEcCtD
Ceftaroline fosamil—Nausea—Vinblastine—testicular cancer	0.00336	0.00336	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Epirubicin—testicular cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00333	0.00333	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Dactinomycin—testicular cancer	0.00328	0.00328	CcSEcCtD
Ceftaroline fosamil—Urticaria—Ifosfamide—testicular cancer	0.00324	0.00324	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Ifosfamide—testicular cancer	0.00322	0.00322	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Ifosfamide—testicular cancer	0.00322	0.00322	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Etoposide—testicular cancer	0.00322	0.00322	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Methotrexate—testicular cancer	0.00317	0.00317	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Etoposide—testicular cancer	0.00315	0.00315	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Epirubicin—testicular cancer	0.00314	0.00314	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Etoposide—testicular cancer	0.00313	0.00313	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Doxorubicin—testicular cancer	0.00309	0.00309	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Dactinomycin—testicular cancer	0.00304	0.00304	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00303	0.00303	CcSEcCtD
Ceftaroline fosamil—Vomiting—Bleomycin—testicular cancer	0.00303	0.00303	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Methotrexate—testicular cancer	0.00302	0.00302	CcSEcCtD
Ceftaroline fosamil—Infestation—Methotrexate—testicular cancer	0.00302	0.00302	CcSEcCtD
Ceftaroline fosamil—Rash—Bleomycin—testicular cancer	0.00301	0.00301	CcSEcCtD
Ceftaroline fosamil—Pain—Cisplatin—testicular cancer	0.00301	0.00301	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Bleomycin—testicular cancer	0.00301	0.00301	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Ifosfamide—testicular cancer	0.003	0.003	CcSEcCtD
Ceftaroline fosamil—Renal failure—Methotrexate—testicular cancer	0.00297	0.00297	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Epirubicin—testicular cancer	0.00297	0.00297	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Doxorubicin—testicular cancer	0.00291	0.00291	CcSEcCtD
Ceftaroline fosamil—Pruritus—Ifosfamide—testicular cancer	0.00288	0.00288	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Epirubicin—testicular cancer	0.00286	0.00286	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Methotrexate—testicular cancer	0.00286	0.00286	CcSEcCtD
Ceftaroline fosamil—Nausea—Bleomycin—testicular cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Infestation—Epirubicin—testicular cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Epirubicin—testicular cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Vomiting—Dactinomycin—testicular cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Rash—Dactinomycin—testicular cancer	0.00281	0.00281	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Ifosfamide—testicular cancer	0.00279	0.00279	CcSEcCtD
Ceftaroline fosamil—Renal failure—Epirubicin—testicular cancer	0.00278	0.00278	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Etoposide—testicular cancer	0.00278	0.00278	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Cisplatin—testicular cancer	0.00278	0.00278	CcSEcCtD
Ceftaroline fosamil—Constipation—Etoposide—testicular cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Pain—Etoposide—testicular cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Doxorubicin—testicular cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Methotrexate—testicular cancer	0.00272	0.00272	CcSEcCtD
Ceftaroline fosamil—Dizziness—Ifosfamide—testicular cancer	0.0027	0.0027	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Methotrexate—testicular cancer	0.00268	0.00268	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Epirubicin—testicular cancer	0.00268	0.00268	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Methotrexate—testicular cancer	0.00266	0.00266	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Doxorubicin—testicular cancer	0.00265	0.00265	CcSEcCtD
Ceftaroline fosamil—Nausea—Dactinomycin—testicular cancer	0.00264	0.00264	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Etoposide—testicular cancer	0.00263	0.00263	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Doxorubicin—testicular cancer	0.00262	0.00262	CcSEcCtD
Ceftaroline fosamil—Infestation—Doxorubicin—testicular cancer	0.00262	0.00262	CcSEcCtD
Ceftaroline fosamil—Vomiting—Ifosfamide—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Cisplatin—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Epirubicin—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Renal failure—Doxorubicin—testicular cancer	0.00257	0.00257	CcSEcCtD
Ceftaroline fosamil—Rash—Ifosfamide—testicular cancer	0.00257	0.00257	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Ifosfamide—testicular cancer	0.00257	0.00257	CcSEcCtD
Ceftaroline fosamil—Urticaria—Etoposide—testicular cancer	0.00256	0.00256	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Etoposide—testicular cancer	0.00255	0.00255	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Etoposide—testicular cancer	0.00255	0.00255	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Epirubicin—testicular cancer	0.00254	0.00254	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Epirubicin—testicular cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Epirubicin—testicular cancer	0.00249	0.00249	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Methotrexate—testicular cancer	0.00246	0.00246	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Methotrexate—testicular cancer	0.00245	0.00245	CcSEcCtD
Ceftaroline fosamil—Nausea—Ifosfamide—testicular cancer	0.00242	0.00242	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Cisplatin—testicular cancer	0.00241	0.00241	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Doxorubicin—testicular cancer	0.00239	0.00239	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Etoposide—testicular cancer	0.00237	0.00237	CcSEcCtD
Ceftaroline fosamil—Erythema—Methotrexate—testicular cancer	0.00236	0.00236	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Methotrexate—testicular cancer	0.00236	0.00236	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Doxorubicin—testicular cancer	0.00235	0.00235	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Doxorubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Epirubicin—testicular cancer	0.00231	0.00231	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Doxorubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Epirubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Pruritus—Etoposide—testicular cancer	0.00228	0.00228	CcSEcCtD
Ceftaroline fosamil—Vomiting—Cisplatin—testicular cancer	0.00224	0.00224	CcSEcCtD
Ceftaroline fosamil—Rash—Cisplatin—testicular cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Cisplatin—testicular cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Epirubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Erythema—Epirubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Etoposide—testicular cancer	0.0022	0.0022	CcSEcCtD
Ceftaroline fosamil—Anaemia—Methotrexate—testicular cancer	0.00218	0.00218	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Doxorubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Ceftaroline fosamil—Dizziness—Etoposide—testicular cancer	0.00213	0.00213	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Doxorubicin—testicular cancer	0.00212	0.00212	CcSEcCtD
Ceftaroline fosamil—Nausea—Cisplatin—testicular cancer	0.00209	0.00209	CcSEcCtD
Ceftaroline fosamil—Convulsion—Methotrexate—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Vomiting—Etoposide—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Doxorubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Erythema—Doxorubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Anaemia—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Ceftaroline fosamil—Rash—Etoposide—testicular cancer	0.00203	0.00203	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Etoposide—testicular cancer	0.00203	0.00203	CcSEcCtD
Ceftaroline fosamil—Headache—Etoposide—testicular cancer	0.00202	0.00202	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.002	0.002	CcSEcCtD
Ceftaroline fosamil—Palpitations—Epirubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Methotrexate—testicular cancer	0.00193	0.00193	CcSEcCtD
Ceftaroline fosamil—Convulsion—Epirubicin—testicular cancer	0.00192	0.00192	CcSEcCtD
Ceftaroline fosamil—Nausea—Etoposide—testicular cancer	0.00191	0.00191	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Methotrexate—testicular cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Anaemia—Doxorubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Methotrexate—testicular cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Methotrexate—testicular cancer	0.00187	0.00187	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Ceftaroline fosamil—Palpitations—Doxorubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Epirubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Ceftaroline fosamil—Convulsion—Doxorubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Epirubicin—testicular cancer	0.00175	0.00175	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Doxorubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00167	0.00167	CcSEcCtD
Ceftaroline fosamil—Pain—Methotrexate—testicular cancer	0.00165	0.00165	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Doxorubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Ceftaroline fosamil—Constipation—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Ceftaroline fosamil—Pain—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Ceftaroline fosamil—Urticaria—Methotrexate—testicular cancer	0.00153	0.00153	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Methotrexate—testicular cancer	0.00152	0.00152	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Methotrexate—testicular cancer	0.00152	0.00152	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Ceftaroline fosamil—Urticaria—Epirubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Constipation—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Pain—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Epirubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Epirubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Methotrexate—testicular cancer	0.00142	0.00142	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Ceftaroline fosamil—Pruritus—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Ceftaroline fosamil—Urticaria—Doxorubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Doxorubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Doxorubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Methotrexate—testicular cancer	0.00132	0.00132	CcSEcCtD
Ceftaroline fosamil—Pruritus—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Dizziness—Methotrexate—testicular cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Ceftaroline fosamil—Vomiting—Methotrexate—testicular cancer	0.00123	0.00123	CcSEcCtD
Ceftaroline fosamil—Rash—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Ceftaroline fosamil—Headache—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Ceftaroline fosamil—Dizziness—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Ceftaroline fosamil—Pruritus—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Ceftaroline fosamil—Vomiting—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Ceftaroline fosamil—Nausea—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Ceftaroline fosamil—Rash—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Ceftaroline fosamil—Headache—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Ceftaroline fosamil—Dizziness—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Nausea—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Ceftaroline fosamil—Vomiting—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Ceftaroline fosamil—Rash—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftaroline fosamil—Headache—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftaroline fosamil—Nausea—Doxorubicin—testicular cancer	0.000992	0.000992	CcSEcCtD
